Carregant...
Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection
In 2016, the US Food and Drug Administration issued a warning about the risk of hepatitis B virus (HBV) reactivation in some patients receiving direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection. HBV reactivation can occur soon after the start of DAA therapy; thus, monitorin...
Guardat en:
| Publicat a: | Gastroenterol Hepatol (N Y) |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Millennium Medical Publishing
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635429/ https://ncbi.nlm.nih.gov/pubmed/29038644 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|